2024-11-10 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops and manufactures a wide range of pharmaceutical products, including treatments for diabetes, cancer, and autoimmune diseases.

**1. Performance Analysis:**

* **Cumulative Return:** LLY has generated a cumulative return of 752.03%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 141.71%. 
* **Relative Performance:** LLY has outperformed the S&P 500 by a considerable margin. The current relative performance is 610.32, placing it in the 76.28th percentile of historical performance against VOO.
* **Alpha & Beta:** LLY exhibits consistent alpha and beta values across different periods. It consistently outperforms the market (positive alpha) with a beta value typically around 0.7, indicating lower volatility compared to the market.

**2. Recent Price Movement:**

* **Closing Price:** 797.45 (Last-market: 831.92)
* **5-day Moving Average:** 800.99
* **20-day Moving Average:** 875.48
* **60-day Moving Average:** 905.97

The recent price movement suggests a potential downtrend. The closing price is below all three moving averages, indicating a short-term bearish sentiment. The last-market price at 831.92 suggests a potential rebound or correction.

**3. Technical Indicators:**

* **RSI:** 18.81 - The RSI is deeply oversold, indicating the potential for a rebound. However, it is important to consider other indicators and factors.
* **PPO:** -1.35 - The PPO is negative, suggesting a bearish sentiment.
* **Delta_Previous_Relative_Divergence:** -15.87 (-) - The recent relative divergence indicates a short-term downtrend. 
* **Expected Return:** 98.22% - This suggests a potential for significant long-term outperformance relative to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-30 | 1.08 | $11.44 B |
| 2024-08-08 | 3.29 | $11.30 B |
| 2024-04-30 | 2.49 | $8.77 B |
| 2023-11-02 | -0.06 | $9.50 B |
| 2024-10-30 | -0.06 | $9.50 B |

The most recent earnings report (2024-10-30) showed an EPS of 1.08, exceeding analyst expectations. Revenue also surpassed estimates, indicating strong performance.  

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $11.44B | 81.02% |
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31 | $8.77B | 80.91% |
| 2023-12-31 | $9.35B | 80.88% |
| 2023-09-30 | $9.50B | 80.42% |

LLY demonstrates consistent revenue growth and a strong profit margin. This indicates robust financial health and profitability.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $14.24B | 6.81% |
| 2024-06-30 | $13.56B | 21.88% |
| 2024-03-31 | $12.81B | 17.51% |
| 2023-12-31 | $10.77B | 20.33% |
| 2023-09-30 | $11.22B | -0.51% |

The company has a solid capital position with a high ROE, highlighting its efficient use of equity to generate profits.

**6. News and Recent Issues:**

* **Recent Earnings Release:** LLY announced its Q3 2024 earnings on October 30th, exceeding analysts' expectations. This news sparked positive market reactions, potentially driving the recent upward price movement. 
* **Market Outlook:**  Analysts have a generally positive outlook on LLY due to its strong financial performance, diversified product portfolio, and growth potential in emerging markets.
* **Analyst Opinions:**  FINBOLD reports that the majority of analysts rate LLY as a “buy” with a consensus price target of $900, suggesting potential upside from current levels.
* **Performance Highlights:**  LLY is highlighted as a top performer in the pharmaceutical sector due to its innovative drug pipeline and consistent revenue growth.

**7. Comprehensive Analysis:**

LLY has consistently outperformed the market, showing strong financial health, robust profitability, and a solid growth trajectory. The recent earnings release further strengthens this positive outlook. While technical indicators suggest a short-term downturn, the overall sentiment remains bullish. The company’s impressive track record of outperforming the market, coupled with its strong fundamentals and positive future prospects, make LLY an attractive investment opportunity for long-term investors. 

**Disclaimer:** This information is for informational purposes only and should not be considered investment advice. 
